Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected
- PMID: 18772725
- DOI: 10.1097/AUD.0b013e31818005a4
Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected
Abstract
Objectives: Bilateral symmetric high frequency hearing loss is regarded as one of the main characteristics of cisplatin-induced ototoxicity. Hair-cell damage because of cisplatin is discussed as the leading cause of hearing loss. Our observations in long-term audiological follow-up of children treated with cisplatin did not always show the anticipated symmetry of hearing loss.
Design: Pure-tone audiograms of 55 (34 m, 21 f) children receiving chemotherapy with cisplatin at Muenster university hospital were analyzed. We compared pure tone hearing thresholds, transient evoked otoacoustic emissions levels and distortion product otoacoustic emissions levels before and after chemotherapy with cisplatin.
Results: After therapy, the 55 children showed slightly higher average hearing levels in the range 2000 to 8000 Hz in the left ear. The side difference was significant at 4000, 6000, and 8000 Hz. In girls, the effect was less pronounced than in boys.
Conclusions: This result, on the one hand, indicates that the auditory system is already responding asymetrically at the cochlear level, on the other hand it underscores the need for further research into the pathophysiology of platinum ototoxicity. There are parallels with stronger effects to the left ear in oiseinduced hearing loss as described in literature. Special attention should be given to possible supracochlear pathways of damage. Clinicians should consider that cisplatin associated hearing loss is not necessarily symmetric.
Similar articles
-
Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.Int J Pediatr Otorhinolaryngol. 2012 Jan;76(1):131-6. doi: 10.1016/j.ijporl.2011.10.020. Epub 2011 Nov 21. Int J Pediatr Otorhinolaryngol. 2012. PMID: 22104469
-
Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.Int J Audiol. 2006 Jun;45(6):337-43. doi: 10.1080/14992020600582117. Int J Audiol. 2006. PMID: 16777780
-
Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.Ear Hear. 2008 Dec;29(6):875-93. doi: 10.1097/AUD.0b013e318181ad99. Ear Hear. 2008. PMID: 18753950 Clinical Trial.
-
Recovery from cisplatin-induced ototoxicity: a case report and review.Int J Pediatr Otorhinolaryngol. 2007 Oct;71(10):1631-8. doi: 10.1016/j.ijporl.2007.06.021. Epub 2007 Aug 15. Int J Pediatr Otorhinolaryngol. 2007. PMID: 17706797 Review.
-
[Research progress on mechanism of cisplatin ototoxicity and protective agents against the ototoxic effects].Sheng Li Ke Xue Jin Zhan. 2003 Jul;34(3):266-9. Sheng Li Ke Xue Jin Zhan. 2003. PMID: 14628479 Review. Chinese. No abstract available.
Cited by
-
Distortion Product Otoacoustic Emissions (DPOAEs) In Tinnitus Patients.Int Arch Otorhinolaryngol. 2021 Mar 29;26(1):e046-e057. doi: 10.1055/s-0040-1722248. eCollection 2022 Jan. Int Arch Otorhinolaryngol. 2021. PMID: 35096158 Free PMC article.
-
Association of Clinical Aspects and Genetic Variants with the Severity of Cisplatin-Induced Ototoxicity in Head and Neck Squamous Cell Carcinoma: A Prospective Cohort Study.Cancers (Basel). 2023 Mar 14;15(6):1759. doi: 10.3390/cancers15061759. Cancers (Basel). 2023. PMID: 36980643 Free PMC article.
-
Evaluation of the protective effect of Cystone against cisplatin-induced nephrotoxicity in cancer patients, and its influence on cisplatin antitumor activity.Int Urol Nephrol. 2014 Jul;46(7):1367-73. doi: 10.1007/s11255-014-0644-y. Epub 2014 Jan 22. Int Urol Nephrol. 2014. PMID: 24448757 Clinical Trial.
-
Quantitative Proteomics of Cochlear Tissues: Bilateral Comparisons in Guinea Pigs and Rats.Proteomics. 2025 Jul;25(13):e13977. doi: 10.1002/pmic.13977. Epub 2025 Jun 23. Proteomics. 2025. PMID: 40545996 Free PMC article.
-
Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma.Neurooncol Pract. 2014 Sep;1(3):86-93. doi: 10.1093/nop/npu017. Epub 2014 Aug 2. Neurooncol Pract. 2014. PMID: 31386031 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources